30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

NewAmsterdam Pharma Company NV (NAMS)

Track

Over the last 90 days, NewAmsterdam Pharma Company NV has seen significant insider selling, with a net value of -$3,528,009. This activity is primarily driven by executives. Notable transactions include large sell-offs by Chief Scientific Officer Johannes Jacob Pieter Kastelein and Chief Accounting Officer Louise Frederika Kooij. The company's stock has experienced an 8.8% increase over the same period.
Stock chart
Ticker: NAMS Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Kooij Louise Frederika
Chief Accounting Officer
2 sales — total 200,000 USD
Sale 22 Jun 2026
Value US$4,867,180.07 | Price 376.47 | Shares 35,211
Sale 22 Jun 2026
Value US$231,521.82 | Price 438.67 | Shares 51,222
Sale 26 May 2026
Value US$2,802,042.65 | Price 170.72 | Shares 95,133
Proposed sale 26 May 2026
Value US$7,442,400.00 | Price 35.44 | Shares 210,000
Sale 11 Mar 2026
Value US$13,928.58 | Price 31.23 | Shares 446
Sale 11 Mar 2026
Value US$1,343,300.93 | Price 30.41 | Shares 44,173
Proposed sale 11 Mar 2026
Value US$1,395,236.13 | Price 31.27 | Shares 44,619
Sale 9 Mar 2026
Value US$3,071,678.61 | Price 30.29 | Shares 101,409
Sale 6 Mar 2026
Value US$828,950.26 | Price 29.41 | Shares 28,186
Sale 6 Mar 2026
Value US$2,853,839.68 | Price 30.32 | Shares 94,124
Proposed sale 6 Mar 2026
Value US$878,839.48 | Price 31.18 | Shares 28,186
Sale 5 Mar 2026
Value US$3,165,350.10 | Price 30.30 | Shares 104,467
Proposed sale 2 Mar 2026
Value US$9,354,000.00 | Price 31.18 | Shares 300,000
Sale 2 Mar 2026
Value US$14,753,257.75 | Price 33.25 | Shares 443,707
Proposed sale 2 Mar 2026
Value US$15,733,850.22 | Price 35.46 | Shares 443,707
Sale 26 Feb 2026
Value US$617,302.56 | Price 34.44 | Shares 17,924
Sale 26 Feb 2026
Value US$5,562,671.04 | Price 33.63 | Shares 165,408
Sale 25 Feb 2026
Value US$47,684.00 | Price 36.68 | Shares 1,300
Sale 25 Feb 2026
Value US$375,278.56 | Price 35.96 | Shares 10,436
Sale 25 Feb 2026
Value US$1,633,211.87 | Price 35.11 | Shares 46,517
Sale 24 Feb 2026
Value US$115,250.06 | Price 36.46 | Shares 3,161
Sale 24 Feb 2026
Value US$2,223,693.11 | Price 36.13 | Shares 61,547
Proposed sale 24 Feb 2026
Value US$27,127,500.00 | Price 36.17 | Shares 750,000
Sale 20 Feb 2026
Value US$1,091,777.94 | Price 35.46 | Shares 30,789
Sale 20 Feb 2026
Value US$514,220.00 | Price 35.00 | Shares 14,692
Proposed sale 20 Feb 2026
Value US$1,575,007.03 | Price 34.63 | Shares 45,481
Sale 28 Jan 2026
Value US$1,037,061.60 | Price 31.80 | Shares 32,612
Sale 27 Jan 2026
Value US$1,298,797.92 | Price 32.62 | Shares 39,816
Sale 26 Jan 2026
Value US$10,336.05 | Price 33.45 | Shares 309
Sale 26 Jan 2026
Value US$1,117,162.07 | Price 32.77 | Shares 34,091
Sale 23 Jan 2026
Value US$438,801.79 | Price 34.37 | Shares 12,767
Sale 23 Jan 2026
Value US$849,543.20 | Price 33.44 | Shares 25,405
Planned sale 21 Jan 2026
Value US$823,435.60 | Price 33.80 | Shares 24,362
Planned sale 21 Jan 2026
Value US$512,781.50 | Price 33.25 | Shares 15,422
Planned sale 20 Jan 2026
Value US$634,777.52 | Price 32.38 | Shares 19,604
Planned sale 20 Jan 2026
Value US$1,262,047.36 | Price 31.78 | Shares 39,712
Planned sale 20 Jan 2026
Value US$27,576.00 | Price 30.64 | Shares 900
Proposed sale 20 Jan 2026
Value US$6,330,000.00 | Price 31.65 | Shares 200,000
Proposed sale 7 Jan 2026
Value US$410,888.61 | Price 35.48 | Shares 11,582
Proposed sale 6 Jan 2026
Value US$10,044,000.00 | Price 33.48 | Shares 300,000
Sale 5 Jan 2026
Value US$199,500.00 | Price 33.25 | Shares 6,000
Sale 5 Jan 2026
Value US$170,173.50 | Price 33.25 | Shares 5,118
Sale 5 Jan 2026
Value US$88,012.75 | Price 33.25 | Shares 2,647
Proposed sale 5 Jan 2026
Value US$88,012.34 | Price 33.25 | Shares 2,647
Proposed sale 5 Jan 2026
Value US$199,499.07 | Price 33.25 | Shares 6,000
Proposed sale 5 Jan 2026
Value US$170,172.71 | Price 33.25 | Shares 5,118
Sale 26 Dec 2025
Value US$1,548,681.60 | Price 35.30 | Shares 43,872
Sale 24 Dec 2025
Value US$928,072.48 | Price 35.68 | Shares 26,011
Sale 23 Dec 2025
Value US$2,719,986.57 | Price 36.21 | Shares 75,117
Proposed sale 23 Dec 2025
Value US$10,582,100.00 | Price 36.49 | Shares 290,000
Proposed sale 2 Dec 2025
Value US$10,250,554.00 | Price 38.33 | Shares 267,429
Proposed sale 2 Dec 2025
Value US$172,485,000.00 | Price 38.33 | Shares 4,500,000
Proposed sale 2 Dec 2025
Value US$1,248,446.00 | Price 38.33 | Shares 32,571
Buy 15 Sep 2025
Value US$15,638.90 | Price 23.70 | Shares 660
Sale 9 Sep 2025
Value US$2,529,954.56 | Price 26.11 | Shares 96,896
Sale 9 Sep 2025
Value US$1,344,062.24 | Price 25.31 | Shares 53,104
Proposed sale 9 Sep 2025
Value US$3,780,000.00 | Price 25.20 | Shares 150,000
Buy 8 Sep 2025
Value US$31,487.40 | Price 24.99 | Shares 1,260
Sale 3 Sep 2025
Value US$453,451.57 | Price 25.09 | Shares 18,073
Proposed sale 3 Sep 2025
Value US$434,655.65 | Price 24.05 | Shares 18,073
Proposed sale 25 Aug 2025
Value US$208,296.11 | Price 25.19 | Shares 8,269
Sale 25 Aug 2025
Value US$205,567.34 | Price 24.86 | Shares 8,269
Sale 22 Aug 2025
Value US$195,202.42 | Price 25.49 | Shares 7,658
Sale 22 Aug 2025
Value US$1,061,937.36 | Price 25.08 | Shares 42,342
Proposed sale 21 Aug 2025
Value US$2,500,000.00 | Price 25.00 | Shares 100,000
Sale 21 Aug 2025
Value US$1,214,500.00 | Price 24.29 | Shares 50,000
Buy 11 Aug 2025
Value US$11,293.97 | Price 23.98 | Shares 471
Planned sale 16 Jul 2025
Value US$1,077,007.30 | Price 21.10 | Shares 51,043
Planned sale 15 Jul 2025
Value US$78,393.28 | Price 22.12 | Shares 3,544
Planned sale 15 Jul 2025
Value US$941,254.50 | Price 21.38 | Shares 44,025
Proposed sale 14 Jul 2025
Value US$30,899,641.10 | Price 21.56 | Shares 1,433,193
Buy 25 Jun 2025
Value US$23,011.63 | Price 18.26 | Shares 1,260
Buy 24 Jun 2025
Value US$46,454.44 | Price 18.43 | Shares 2,520
Proposed sale 16 Jun 2025
Value US$5,912,341.50 | Price 19.50 | Shares 303,197
Planned sale 16 Jun 2025
Value US$357,652.75 | Price 19.75 | Shares 18,109
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-22 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
35,211 -29.3%
376.47
US$4,867,180 		35,211 -29.3% 376.47 US$4,867,180
2026-06-24 2026-06-22 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
51,222 +5.4%
438.67
US$231,522 		51,222 +5.4% 438.67 US$231,522
2026-05-27 2026-05-26 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
95,133 +5.8%
170.72
US$2,802,043 		95,133 +5.8% 170.72 US$2,802,043
2026-05-26 2026-05-26 PrS Proposed sale
2.6
Louise Kooij

Officer

Officer
210,000
35.44
US$7,442,400 		210,000 35.44 US$7,442,400
2026-03-12 2026-03-11 S Sale
2.4
LANGE LOUIS G
Non-Executive Director
446 -4.1%
31.23
US$13,929 		446 -4.1% 31.23 US$13,929
2026-03-12 2026-03-11 S Sale
2.4
LANGE LOUIS G
Non-Executive Director
44,173 -80.3%
30.41
US$1,343,301 		44,173 -80.3% 30.41 US$1,343,301
2026-03-11 2026-03-11 PrS Proposed sale
2.4
Louis G. Lange

Affiliate
44,619
31.27
US$1,395,236 		44,619 31.27 US$1,395,236
2026-03-09 2026-03-09 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
101,409 -59.4%
30.29
US$3,071,679 		101,409 -59.4% 30.29 US$3,071,679
2026-03-10 2026-03-06 S Sale
2.4
LANGE LOUIS G
Non-Executive Director
28,186 -100.0%
29.41
US$828,950 		28,186 -100.0% 29.41 US$828,950
2026-03-09 2026-03-06 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
94,124 -57.6%
30.32
US$2,853,840 		94,124 -57.6% 30.32 US$2,853,840
2026-03-06 2026-03-06 PrS Proposed sale
2.4
Louis G. Lange

Affiliate
28,186
31.18
US$878,839 		28,186 31.18 US$878,839
2026-03-09 2026-03-05 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
104,467 -60.1%
30.30
US$3,165,350 		104,467 -60.1% 30.30 US$3,165,350
2026-03-05 2026-03-02 PrS Proposed sale
2.3
Kastelein Johannes Jacob Pieter

Affiliate
300,000
31.18
US$9,354,000 		300,000 31.18 US$9,354,000
2026-03-02 2026-03-02 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
443,707 -71.8%
33.25
US$14,753,258 		443,707 -71.8% 33.25 US$14,753,258
2026-03-02 2026-03-02 PrS Proposed sale
3.0
Michael H. Davidson

Affiliate
443,707
35.46
US$15,733,850 		443,707 35.46 US$15,733,850
2026-02-26 2026-02-26 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
17,924 -9.3%
34.44
US$617,303 		17,924 -9.3% 34.44 US$617,303
2026-02-26 2026-02-26 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
165,408 -25.7%
33.63
US$5,562,671 		165,408 -25.7% 33.63 US$5,562,671
2026-02-26 2026-02-25 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
1,300 -0.3%
36.68
US$47,684 		1,300 -0.3% 36.68 US$47,684
2026-02-26 2026-02-25 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
10,436 -2.2%
35.96
US$375,279 		10,436 -2.2% 35.96 US$375,279
2026-02-26 2026-02-25 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
46,517 -9.0%
35.11
US$1,633,212 		46,517 -9.0% 35.11 US$1,633,212
2026-02-26 2026-02-24 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
3,161 -0.7%
36.46
US$115,250 		3,161 -0.7% 36.46 US$115,250
2026-02-26 2026-02-24 S Sale
3.0
Davidson Michael H.

Chief Executive Officer

Executive Director
61,547 -11.7%
36.13
US$2,223,693 		61,547 -11.7% 36.13 US$2,223,693
2026-02-24 2026-02-24 PrS Proposed sale
3.0
Michael H. Davidson

Affiliate
750,000
36.17
US$27,127,500 		750,000 36.17 US$27,127,500
2026-02-24 2026-02-20 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
30,789 -36.5%
35.46
US$1,091,778 		30,789 -36.5% 35.46 US$1,091,778
2026-02-24 2026-02-20 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
14,692 -14.8%
35.00
US$514,220 		14,692 -14.8% 35.00 US$514,220
2026-02-20 2026-02-20 PrS Proposed sale
2.3
Kastelein Johannes Jacob Pieter

Officer; Director

Executive Director
45,481
34.63
US$1,575,007 		45,481 34.63 US$1,575,007
2026-01-29 2026-01-28 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
32,612 -57.2%
31.80
US$1,037,062 		32,612 -57.2% 31.80 US$1,037,062
2026-01-29 2026-01-27 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
39,816 -62.0%
32.62
US$1,298,798 		39,816 -62.0% 32.62 US$1,298,798
2026-01-27 2026-01-26 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
309 -1.3%
33.45
US$10,336 		309 -1.3% 33.45 US$10,336
2026-01-27 2026-01-26 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
34,091 -58.0%
32.77
US$1,117,162 		34,091 -58.0% 32.77 US$1,117,162
2026-01-27 2026-01-23 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
12,767 -34.4%
34.37
US$438,802 		12,767 -34.4% 34.37 US$438,802
2026-01-27 2026-01-23 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
25,405 -40.6%
33.44
US$849,543 		25,405 -40.6% 33.44 US$849,543
2026-01-22 2026-01-21 PlS Planned sale
2.2
Somaiya Mayur Ian

Chief Financial Officer

Officer
24,362 -29.4%
33.80
US$823,436 		24,362 -29.4% 33.80 US$823,436
2026-01-22 2026-01-21 PlS Planned sale
2.2
Somaiya Mayur Ian

Chief Financial Officer

Officer
15,422 -15.7%
33.25
US$512,782 		15,422 -15.7% 33.25 US$512,782
2026-01-22 2026-01-20 PlS Planned sale
2.2
Somaiya Mayur Ian

Chief Financial Officer

Officer
19,604 -25.1%
32.38
US$634,778 		19,604 -25.1% 32.38 US$634,778
2026-01-22 2026-01-20 PlS Planned sale
2.2
Somaiya Mayur Ian

Chief Financial Officer

Officer
39,712 -33.7%
31.78
US$1,262,047 		39,712 -33.7% 31.78 US$1,262,047
2026-01-22 2026-01-20 PlS Planned sale
2.2
Somaiya Mayur Ian

Chief Financial Officer

Officer
900 -0.8%
30.64
US$27,576 		900 -0.8% 30.64 US$27,576
2026-01-20 2026-01-20 PrS Proposed sale
2.2
Mayur Somaiya

Affiliate
200,000
31.65
US$6,330,000 		200,000 31.65 US$6,330,000
2026-01-07 2026-01-07 PrS Proposed sale
3.0
Michael Davidson

affiliate
11,582
35.48
US$410,889 		11,582 35.48 US$410,889
2026-01-06 2026-01-06 PrS Proposed sale
Douglas F Kling

Affiliate
300,000
33.48
US$10,044,000 		300,000 33.48 US$10,044,000
2026-01-07 2026-01-05 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
6,000 -7.5%
33.25
US$199,500 		6,000 -7.5% 33.25 US$199,500
2026-01-07 2026-01-05 S Sale
2.2
Somaiya Mayur Ian

Chief Financial Officer

Officer
5,118 -13.5%
33.25
US$170,174 		5,118 -13.5% 33.25 US$170,174
2026-01-07 2026-01-05 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
2,647 -17.6%
33.25
US$88,013 		2,647 -17.6% 33.25 US$88,013
2026-01-05 2026-01-05 PrS Proposed sale
2.6
Louise Kooij

affiliate
2,647
33.25
US$88,012 		2,647 33.25 US$88,012
2026-01-05 2026-01-05 PrS Proposed sale
2.3
Johannes Kastelein

Affiliate
6,000
33.25
US$199,499 		6,000 33.25 US$199,499
2026-01-05 2026-01-05 PrS Proposed sale
2.2
Mayur Ian Somaiya

affiliate
5,118
33.25
US$170,173 		5,118 33.25 US$170,173
2025-12-29 2025-12-26 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
43,872 -74.5%
35.30
US$1,548,682 		43,872 -74.5% 35.30 US$1,548,682
2025-12-29 2025-12-24 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
26,011 -63.4%
35.68
US$928,072 		26,011 -63.4% 35.68 US$928,072
2025-12-29 2025-12-23 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
75,117 -83.4%
36.21
US$2,719,987 		75,117 -83.4% 36.21 US$2,719,987
2025-12-23 2025-12-23 PrS Proposed sale
2.6
Louise Kooij

Officer

Officer
290,000
36.49
US$10,582,100 		290,000 36.49 US$10,582,100
2025-12-02 2025-12-02 PrS Proposed sale
Bain Capital Life Sciences Fund II, L.P.

Former Affiliate
267,429
38.33
US$10,250,554 		267,429 38.33 US$10,250,554
2025-12-02 2025-12-02 PrS Proposed sale
BCLS II Investco, LP

Former Affiliate
4,500,000
38.33
US$172,485,000 		4,500,000 38.33 US$172,485,000
2025-12-02 2025-12-02 PrS Proposed sale
BCIP Life Sciences Associates, LP

Former Affiliate
32,571
38.33
US$1,248,446 		32,571 38.33 US$1,248,446
2025-09-17 2025-09-15 B Purchase
3.7
Topper James N
Non-Executive Director
660 +0.0%
23.70
US$15,639 		660 +0.0% 23.70 US$15,639
2025-09-10 2025-09-09 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
96,896 -86.6%
26.11
US$2,529,955 		96,896 -86.6% 26.11 US$2,529,955
2025-09-10 2025-09-09 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
53,104 -32.2%
25.31
US$1,344,062 		53,104 -32.2% 25.31 US$1,344,062
2025-09-09 2025-09-09 PrS Proposed sale
2.6
Louise Kooij

Affiliate
150,000
25.20
US$3,780,000 		150,000 25.20 US$3,780,000
2025-09-10 2025-09-08 B Purchase
3.7
Topper James N
Non-Executive Director
1,260 +0.0%
24.99
US$31,487 		1,260 +0.0% 24.99 US$31,487
2025-09-05 2025-09-03 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
18,073 -54.6%
25.09
US$453,452 		18,073 -54.6% 25.09 US$453,452
2025-09-03 2025-09-03 PrS Proposed sale
2.6
Kooij Louise Frederika

Officer

Officer
18,073
24.05
US$434,656 		18,073 24.05 US$434,656
2025-08-27 2025-08-25 PrS Proposed sale
2.6
Kooij Louise Frederika

Officer

Officer
8,269
25.19
US$208,296 		8,269 25.19 US$208,296
2025-08-27 2025-08-25 S Sale
2.6
Kooij Louise Frederika

Chief Accounting Officer

Officer
8,269 -35.5%
24.86
US$205,567 		8,269 -35.5% 24.86 US$205,567
2025-08-25 2025-08-22 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
7,658 -10.0%
25.49
US$195,202 		7,658 -10.0% 25.49 US$195,202
2025-08-25 2025-08-22 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
42,342 -35.5%
25.08
US$1,061,937 		42,342 -35.5% 25.08 US$1,061,937
2025-08-25 2025-08-21 PrS Proposed sale
2.3
Kastelein Johannes Jacob Pieter

Officer; Director

Executive Director
100,000
25.00
US$2,500,000 		100,000 25.00 US$2,500,000
2025-08-25 2025-08-21 S Sale
2.3
Kastelein Johannes Jacob Pieter

Chief Scientific Officer

Executive Director
50,000 -29.5%
24.29
US$1,214,500 		50,000 -29.5% 24.29 US$1,214,500
2025-08-13 2025-08-11 B Purchase
3.7
Topper James N
Non-Executive Director
471 +0.0%
23.98
US$11,294 		471 +0.0% 23.98 US$11,294
2025-07-17 2025-07-16 PlS Planned sale
Kling Douglas F

Chief Operating Officer

Officer
51,043 -53.7%
21.10
US$1,077,007 		51,043 -53.7% 21.10 US$1,077,007
2025-07-17 2025-07-15 PlS Planned sale
Kling Douglas F

Chief Operating Officer

Officer
3,544 -7.5%
22.12
US$78,393 		3,544 -7.5% 22.12 US$78,393
2025-07-17 2025-07-15 PlS Planned sale
Kling Douglas F

Chief Operating Officer

Officer
44,025 -48.1%
21.38
US$941,254 		44,025 -48.1% 21.38 US$941,254
2025-07-14 2025-07-14 PrS Proposed sale
NAP PoolCo B.V.

Affiliate
1,433,193
21.56
US$30,899,641 		1,433,193 21.56 US$30,899,641
2025-06-26 2025-06-25 B Purchase
3.7
Topper James N
Non-Executive Director
1,260 +0.0%
18.26
US$23,012 		1,260 +0.0% 18.26 US$23,012
2025-06-26 2025-06-24 B Purchase
3.7
Topper James N
Non-Executive Director
2,520 +0.1%
18.43
US$46,454 		2,520 +0.1% 18.43 US$46,454
2025-06-18 2025-06-16 PrS Proposed sale
NAP PoolCo B.V.

Affiliate
303,197
19.50
US$5,912,342 		303,197 19.50 US$5,912,342
2025-06-18 2025-06-16 PlS Planned sale
Kling Douglas F

Chief Operating Officer

Officer
18,109 -29.2%
19.75
US$357,653 		18,109 -29.2% 19.75 US$357,653
Explore more

More insider trading research around NewAmsterdam Pharma Company NV

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America